🧾 What This Document Is

This is a DEF 14A, or "Proxy Statement," for The Joint Corp (JYNT). Think of it as a detailed invitation and information packet for the company's annual shareholder meeting. It's filed with the SEC ahead of the meeting to give shareholders all the information they need to vote on important issues.

Why it matters: This document is your one-stop shop to understand the company's performance, the people running it, how they are paid, and the key decisions shareholders will be voting on. It’s about accountability and corporate governance.

The 2026 Annual Meeting will be held virtually on Wednesday, May 20, 2026, at 8:00 a.m. Pacific Time.

🏢 What The Company Does

👉 In simple terms, The Joint Corp is a franchisor of chiropractic clinics. They operate a membership-based model, making chiropractic care more like a subscription service. Their clinics are in accessible retail settings, not traditional medical offices.

They are in the midst of a major strategic shift: moving from owning and operating some clinics to becoming a "pure-play franchisor," meaning they will mainly collect franchise fees and royalties from clinic owners. This is a lighter, less capital-intensive business model.

💰 Financial & Operational Highlights (2025)

The company had a strong 2025, returning to profitability and growing key metrics:

• Revenue: $54.9 million (up from $52.2 million in 2024).
• Net Income: $2.9 million profit, a significant turnaround from a $5.8 million loss in 2024.
• Adjusted EBITDA: $13.0 million (up 13.9% from $11.4 million).
• System-Wide Sales: $532.4 million across all clinics (franchisee and company-owned).
• Clinic Network: 960 total clinics (885 franchised, 75 company-owned).
• Patients: 1.7 million unique patients treated, with 797,000 new patients.

👉 Why it matters: The return to profitability and growth in Adjusted EBITDA show the business model is working. The high number of new patients (41% new to chiropractic) suggests they are expanding the market for their services.

🚀 Key Strategic Move: Becoming a Pure-Play Franchisor

The biggest story here is the company's aggressive push to sell its company-owned clinics to franchisees.

• Progress: Sold 41 clinics to franchisees in 2025. Signed agreements to sell 22 more and have Letters of Intent for 5 more.
• Result: They now have only 48 company-owned clinics left (about 5% of the total). They aim to complete this transition by the end of 2026.
• Expected Outcome: Once complete, The Joint expects a much more efficient business with:
  • Adjusted EBITDA margin: 19% to 21%
  • Net Income margin: 13% to 15%
  • Free Cash Flow conversion: 60% to 70%

👉 Why it matters: This move should dramatically improve profitability and cash flow. It reduces operational complexity and risk, allowing the company to focus on its core strength: franchising.

👥 Who Runs the Show: Board Nominees

Shareholders will vote to elect seven directors. The board has a mix of franchise, finance, and branding experts.

• Lead Director: Matthew E. Rubel (franchise & retail expert).
• New Nominees: The slate includes two new director nominees with deep franchise experience:
  • Christopher M. Grandpre: Former CEO of a multi-brand franchise company (Empower Brands).
  • Sandra R.A. Karrmann: Former Chief HR Officer at major corporations like Kimberly-Clark and Yum! Brands.
• CEO on the Board: Sanjiv Razdan, the President and CEO, is also a director.

👉 Why it matters: The board is being refreshed with expertise (like Mr. Grandpre's) directly relevant to The Joint's future as a pure franchisor. Strong franchise knowledge at the board level is crucial for this strategy.

💸 Executive Compensation (Say-on-Pay Vote)

Shareholders will cast an advisory vote to approve executive compensation. The proxy details the pay for the top executives for 2025.

• Highest-Paid: CEO Sanjiv Razdan's total compensation was $1,505,519. This includes salary, stock awards, and option awards.
• Philosophy: Pay is set by the Compensation Committee, which uses data from consultant Korn Ferry to benchmark against peer companies. The goal is to tie pay to company performance and individual contributions.

👉 Why it matters: This is your chance as a shareholder to voice approval or disapproval of how leadership is paid. It's a key governance tool.

🔮 What's Next: "Joint 3.0"

Management is looking beyond the current "Joint 2.0" refranchising plan.

• Joint 3.0: The next growth phase starting in 2027, focused on:
  • Expanding into new geographic markets.
  • Developing business-to-business (B2B) channels.
  • Exploring international expansion.
  • Enhancing services (integrated treatments, nutrition, orthotics).
• Near-Term Focus: For 2026, the priority is finishing the refranchising, improving marketing, and testing new pricing to drive same-store sales.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths:

• Proven Model: 15-year compound annual growth rate (CAGR) of 38% vastly outpaces the industry.
• Clear Strategy: The path to becoming a pure franchisor is well-defined and nearly complete.
• Recurring Revenue: 85% of revenue comes from recurring memberships.

⚠️ Risks & Challenges:

• Growth Slowdown: System-wide sales grew only 0.4% in 2025, and same-store sales were down 0.4%.
• Execution Risk: Success depends on franchisees executing well on operations, marketing, and new pricing.
• Franchise Sales: Only 31 new franchise licenses were sold in 2025, down from 57 in 2024. Future network growth depends on this.

🧠 The Analogy

The Joint Corp is like a homeowner (the company) deciding to stop being a landlord (operating clinics) and instead become a full-time property manager and sales agent for their houses (franchising). They're selling off the houses they own to focus on what they do best: finding new homeowners (franchisees), helping them succeed, and collecting a steady management fee (royalties). The early results from this strategy are boosting their profitability.

🧩 Final Takeaway

The Joint Corp is on the verge of a major transformation into a streamlined, higher-margin franchisor. The 2025 results prove the concept is working financially. The key for shareholders is to watch if the company can reignite same-store sales growth and franchise sales to power the next chapter ("Joint 3.0") of its story after the refranchising is complete.